Cerivastatin Sodium

Drug #1827

HMG-CoA reductase inhibitor, is a lipid regulating drug. It is mainly used in the treatment of hypercholesterolemia.

← Previous drug Next drug →

Primary Characteristics

Cerivastatin Sodium is also known as .

It is of Synthetic origin and belongs to Anti-hyperlipidimic.

It belongs to dyslipidaemic agent pharmacological group on the basis of mechanism of action.

Molecular Weight: 481.5 · Non-proprietary name: Cerivastatin Sodium.

Molecular structure of Cerivastatin Sodium

Pharmacokinetics

Absorption: Cerivastatin Sodium has an oral bioavailability is 30% (±30%).

Distribution: Cerivastatin Sodium has a plasma protein binding is 99%.

Elimination: it is metabolised via 70%, plasma half-life is 2-3 hrs, renal excretion is 30%.

Indications

Cerivastatin Sodium is primarily indicated in conditions like Hyperlipoproteinaemia.

Cerivastatin Sodium is also indicated for secondary conditions like Hypercholesterolaemia.

Contraindications

Cerivastatin Sodium is contraindicated in conditions like Porphyria, Acute liver disease.

Dosage

Cerivastatin Sodium's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.5 mg	0.5 mg	Every 24h	PO	In the evening, initially.
100 ug	100 ug	—	PO	At intervals of at least 4 weeks up to a max. of 300 ug once daily.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

15 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Cerivastatin Sodium are ACUTE RHABDOMYLOSIS, Acute renal failure.

Cerivastatin Sodium is known to cause more or less tolerable side effects which are usually transient. These include Blurred vision, dizziness, Dysgeusia, Headache, Insomnia, Skin rashes.

Warnings / Precautions

It should be avoided during pregnancy since there is a possibility that it could interfere with fetal sterol synthesis. It should be discontinued if marked or persistant increases in serum aminotransferase or creatine-phosphokinase concentrations occur.It shouls not be given in severe renal impairement and liver function should be monitored

Available Brands

None recorded.

Storage Conditions

Cerivastatin Sodium should be stored Tabs.

Drug Classification

1.12.6 — Lipid-regulating drugs /Anti-atheromas